AMAR’s development partners are Hayashibara Biochemical Laboratories, CytoPharm, Bumimedic, and Intas Pharma.  Contact information for each partner is provided below along with a brief summary of the activities of each.

CytoPharm, Inc.

6^th Fl., No.6, Sec 1, Jungshing Road Wugu Shiang, Taipei County 248 Taiwan

CytoPharm has a license and supply agreement for Taiwan and China. CytoPharm has an ongoing Phase 2 study in Taiwan aimed at prevention of relapse in 165 patients chronically infected with the hepatitis C virus. CytoPharm plans to conduct a Phase 2 influenza treatment study in 2011.

Bumimedic (Malaysia)

Sdn. Bhd. No. 3, Jalan 19/1, 16300 Petaling Jaya, Selangor, Malaysia

Bumimedic has a license and supply agreement for Malaysia.

Intas Pharma (http://www.intaspharma.com)

Chinubhai Center, Off Nehru Bridge, Ashram Road, 380 009, Gujarat, India

Intas has a license and supply agreement for India and Nepal for the clinical indication of influenza.